Viskase Holdings, Inc. balance sheet VISK

Annual Quarterly

As of Sep 30, 2026, Viskase Holdings, Inc. had total assets of $427.5 million. Total assets were up 878.3% from a year earlier. Stockholders' equity was $178.9 million. It held $7.7 million in cash and investments against $290.6 million of total debt, net debt of $282.9 million. The current ratio, current assets divided by current liabilities, was 1.07.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Assets
Cash	8 -82.1%	8 -82.1%	29 -36.4%	9 -80.3%	43 -7.2%	44 -4.2%	45 -2.2%	47 -0.3%
Cash and investments	8 -82.1%	8 -82.1%	29 -36.4%	9 -80.3%	43 -7.2%	44 -4.2%	45 -2.2%	47 -0.3%
Receivables	70	67	63	—	—	—	—	—
Inventory	100	105	99	—	—	—	—	—
Total current assets	226 +418.3%	227 +408.2%	235 +415.3%	209 +342.5%	44 -7.0%	45 -4.1%	46 -2.0%	47 -0.4%
Property and equipment, net	156	148	143	—	—	—	—	—
Goodwill	3	3	3	—	—	—	—	—
Total assets	427 +878.3%	424 +847.9%	429 +842.1%	402 +752.6%	44 -7.6%	45 -4.7%	46 -2.8%	47 -1.1%
Liabilities and equity
Accounts payable	43 +12876.4%	39 +11810.6%	37 +11045.9%	44 +13296.4%	0 +0.0%	0 +0.0%	0 +0.0%	0 +0.0%
Total current liabilities	211 +38923.9%	124 +15296.0%	117 +21007.8%	215 +12684.1%	1 +23.3%	1 +95.9%	1 +6.3%	2 -2.1%
Stockholders' equity	179 +19487.2%	187 +43140.7%	192 +9741.3%	146 +4748.5%	-1 -133.4%	0 -85.8%	2 -40.7%	3 +185.8%
Debt
Debt due within a year	136	54	51	—	—	—	—	—
Long-term debt	136	129	131	—	—	—	—	—
Lease liabilities	19	20	21	—	—	—	—	—
Total debt	291	204	203	—	—	—	—	—
Net cash	-283	-196	-174	—	—	—	—	—
Ratios
Current ratio	1.07x	1.84x	2.01x	0.97x	80.86x	55.71x	82.17x	28.10x
Debt to equity	1.62x	1.09x	1.06x	—	—	—	—	—
Return on equity	14.11%	10.00%	1.81%	-2.34%	—	-7,789.12%	-672.15%	25.86%
Return on assets	5.91%	4.40%	0.81%	-0.85%	-107.31%	-75.14%	-28.84%	1.65%
Book value per share	12.49	13.03	13.41	22.06	-0.01	0.01	0.03	0.04

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: VISK (OTC)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Lombard, IL
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 727510
Former names: ENZON PHARMACEUTICALS, INC. (until Mar 25, 2026); ENZON PHARMACEUTICALS INC (until Feb 23, 2016); ENZON PHARMACEUTICALS INC (until Mar 22, 2006); ENZON PHARMACEUTICAL INC (until Dec 10, 2002); ENZON INC (until Dec 9, 2002)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.